Demystifying M&A Valuation Chinese 估值是每笔交易中最关键的部分，但它往往是最不被理解的部分。与Ascento Capital的管理合伙人本·博伊塞万（Ben Boissevain）一起探讨估值的细微差别、估值框架以及正确估值的流程。 Mergers & Acquisitions Valuation Whitepapers
Demystifying Tech M&A Valuation korean 가치 평가는 모든 거래에서 가장 중요한 부분이지만 중요한 만큼 이해가 어려운 분야입니다. 아센토 캐피털의 매니징 파트너인 벤 보이세빈 (Ben Boissevain)과 함께 "가치 평가"라는 단어의 의미, 개요 및 가치 평가를 성공적으로 처리하기 위한 과정을 알아보십시오. Technology Valuation Whitepapers
Cybersecurity Best Practices for 2021 If cybersecurity is not on the top of your company's list of initiatives for 2021, then it should be, and even if it is, you may not be doing enough. Best Practices & Trends Security Webinars
Valuation of Your Early Drug Candidate In this whitepaper, author Linda Pullan reviews the different techniques, key variables, and characteristics of what makes a drug candidate more valuable to a partner. Life Sciences Series Valuation Whitepapers
Getting Ready for a Biopharma Partnering Deal This whitepaper provides actionable advice for Biotech business development leaders on how to get ready for a partnering deal. Best Practices & Trends BioPharma Licensing & Partnering Life Sciences Series Whitepapers
Must-Know Finance Concepts for Life Sciences Valuations - Part II This whitepaper discusses which asset valuation methodology is most used by big pharma to evaluate possible partners or acquisitions and an explanation of three fundamental concepts in valuation: risk-adjusted value, cost of capital, and present value. Best Practices & Trends BioPharma Life Sciences Valuation Whitepapers
Demystifying Tech M&A Valuation In this whitepaper, explore the nuances of valuation, its framework and the processes for getting it right. Best Practices & Trends Finance Mergers & Acquisitions Other Topics Valuation Whitepapers
Must-Know Finance Concepts for Life Sciences Valuations This whitepaper presents an introduction to the key concepts and most common methodologies used to evaluate life sciences assets. Best Practices & Trends BioPharma Life Sciences Valuation Whitepapers
The Nuts & Bolts of Due Diligence in Biopharma Partnering This whitepaper focuses on best practices in due diligence with the goal of forming productive biopharma partnerships. Best Practices & Trends BioPharma Due Diligence Licensing & Partnering Life Sciences Series Whitepapers
What's Hot and What's Not in Oncology Licensing in 2020? In this whitepaper, Linda Pullan, PhD of Pullan Consulting and our panel of experts provided insights in oncology and immuno-oncology in 2020. Best Practices & Trends BioPharma Life Sciences Other Topics Series Whitepapers
How to Win at the Partnering Game In this white paper, Linda Pullan provides a review of the rules of the partnering game – whether it’s partnering from preclinical to late clinical development – to provide an understanding of what to expect in moving from introductions to negotiations of a license or acquisition and how to win with a clear strategy. Best Practices & Trends BioPharma Licensing & Partnering Life Sciences Series Whitepapers
Demystifying Tech M&A Valuation This webinar explores the nuances of valuation, its framework, and the processes for getting it right in the mergers and acquisitions process. Finance Mergers & Acquisitions Other Topics Valuation Webinars